Abstract
Introduction: GINA 2020 recommends medium- and high-dose ICS/LABA, respectively, as preferred controller for GINA step 4 and 5, with add-on TIO as option for step 5. Once-daily (o.d.) MF/IND and MF/IND/GLY at different ICS doses provide novel treatment options in patients across asthma severities
Methods: Medium-dose MF/IND and MF/IND/GLY (160/150µg and 80/150/50µg) and, respective, high-dose (320/150µg and 160/150/50µg) o.d. vs widely used therapy, high-dose FLU/SAL (500/50µg) and high-dose FLU/SAL+TIO (5µg) twice-daily were assessed for trough FEV1, ACQ-7 and exacerbations in PLATINUM program comprising PALLADIUM, IRIDIUM and ARGON studies
Results: Comparison of MF/IND vs FLU/SAL; MF/IND/GLY vs FLU/SAL and FLU/SAL+TIO for trough FEV1, ACQ-7 and exacerbations are presented in Table. Improvement in trough FEV1 was observed with both doses of MF/IND/GLY vs FLU/SAL (Wk 26) and high-dose MF/IND/GLY vs FLU/SAL+TIO (Wk 24). Exacerbation reduction over 52 wks was greater with high-dose MF/IND/GLY vs FLU/SAL. Improvements in trough FEV1 and ACQ-7 were maintained until Wk 52. All treatments were well tolerated
Conclusion: MF/IND and MF/IND/GLY demonstrated clinical benefit vs widely used asthma treatments and represent novel o.d. treatment options for patients with inadequately controlled asthma
Footnotes
Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3385.
This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2021